Patents by Inventor Linda Mulcahy

Linda Mulcahy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
    Patent number: 6890921
    Abstract: This invention relates to a series of arylsubstituted piperazines, of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the ?-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: May 10, 2005
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Linda Jolliffe, William Murray, Virginia Pulito, Allen Reitz, Xiaobing Li, Linda Mulcahy, Cynthia Maryanoff, Frank Villani
  • Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
    Publication number: 20030220493
    Abstract: This invention relates to a series of arylsubstituted piperazines, of Formula I 1
    Type: Application
    Filed: June 2, 2003
    Publication date: November 27, 2003
    Inventors: Linda Jolliffe, William Murray, Virginia Pulito, Allen Reitz, Xiaobing Li, Linda Mulcahy, Cynthia Maryanoff, Frank Villani
  • Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
    Patent number: 6593474
    Abstract: This invention relates to a series of arylsubstituted piperazines, of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: July 15, 2003
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Linda Jolliffe, William Murray, Virginia Pulito, Linda Mulcahy, Xiaobing Li, Allen Reitz, Cynthia Maryanoff, Frank Villani
  • Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
    Patent number: 6303594
    Abstract: This invention relates to a series of arylsubstituted piperazines, of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: October 16, 2001
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Linda Jolliffe, William Murray, Virginia Pulito, Allan Reitz, Xiaobing Li, Linda Mulcahy, Cynthia Maryanoff, Frank Villani
  • Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
    Patent number: 6071915
    Abstract: This invention relates to a series of arylsubstituted piperazines, of Formula I ##STR1## pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the .alpha.-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: June 6, 2000
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Linda Jolliffe, William Murray, Virginia Pulito, Allen Reitz, Xiaobing Li, Linda Mulcahy, Cynthia Maryanoff, Frank Villani
  • Compounds and peptides that bind to the erythropoietin receptor
    Patent number: 5773569
    Abstract: Peptides of 10 to 40 or more amino acid residues in length and having the sequence X.sub.3 X.sub.4 X.sub.5 GPX.sub.6 TWX.sub.7 X.sub.8 (SEQ ID NO:252) where each amino acid is indicated by standard one letter abbreviation; X.sub.3 is C; X.sub.4 is R, H, L, or W; X.sub.5 is M, F, or I; X.sub.6 is independently selected from any one of the 20 genetically coded L-amino acids; X.sub.7 is D, E, I, L, or V; and X.sub.8 is C, which bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist, and methods for their use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 30, 1998
    Assignee: Affymax Technologies N.V.
    Inventors: Nicholas C. Wrighton, William J. Dower, Ray S. Chang, Arun K. Kashyap, Linda K. Jolliffe, Dana Johnson, Linda Mulcahy